StemRIM (TYO: 4599)

Market Cap	19.48B
Revenue (ttm)	n/a
Net Income (ttm)	-2.12B
Shares Out	62.04M
EPS (ttm)	-34.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	239,200
Open	296.00
Previous Close	297.00
Day's Range	296.00 - 317.00
52-Week Range	285.00 - 620.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 11, 2024

About StemRIM

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. St...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 45
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4599